One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia
Diagnostics · 15.07.2026 · 16 (14) · 2216
DOI: 10.3390/diagnostics16142216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 15.07.2026. Verfasst von Mirjana Suver Stević und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Quantitative PCR measurement of BCR::ABL1 is essential for monitoring molecular response and detecting relapse in chronic myeloid leukemia (CML) patients. Given the availability of multiple commercial kits for cDNA synthesis and minimal residual disease assessment, analytical accuracy and reliability are critical. This study evaluated two commercial RT and qPCR kits for BCR::ABL1 quantification and fusion transcript variant identification.
Methods
Total RNA was isolated from peripheral blood, bone marrow, and external quality control samples from the UK NEQAS for Leucocyte Immunophenotyping program. cDNA synthesis was performed using two kits: AffinityScript (ASK) and RT Kit (RTK). BCR::ABL1 transcript levels were determined using the ipsogen® BCR-ABL1 Mbcr IS-MMR Kit (IPS) and the LightMix® bcr-abl t(9;22) M/m/µ Kit (TMB). Results were compared with UK NEQAS LI reference data. Fusion transcript variants were analyzed using nested PCR and a commercial qPCR assay.
Results
Substantial variability was observed between the TMB and IPS assays, with moderate, non-significant correlation and wide limits of agreement. Established discrepancies resulted in different classifications of molecular response, and IPS results showed better concordance with external quality assessment data. ABL1 quantification revealed significantly higher copy numbers with the RTK compared to the ASK (p < 0.0001), enabling more reliable assessment of deep molecular responses. Statistical analyses indicated systematic and proportional bias between the methods. For variant detection, nested PCR demonstrated higher specificity, while the commercial assay showed limited discriminatory capability.
Conclusions
Significant methodological differences may affect clinical interpretation, underscoring the importance of validation and standardization in CML molecular monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia.
- Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia.
- Department of Biology, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia.
ORCID-Profile: Mirjana Suver Stević, Vlatka Periša
Zitieren
APA
Suver Stević, M., Periša, V., Vujičić, K., Marczi, S., Sinčić-Petričević, J., & Mjeda, D. (2026). One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia. Diagnostics, 16(14), 2216. https://doi.org/10.3390/diagnostics16142216
Vancouver
Suver Stević M, Periša V, Vujičić K, Marczi S, Sinčić-Petričević J, Mjeda D. One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia. Diagnostics. 2026;16(14):2216. doi:10.3390/diagnostics16142216
BibTeX
@article{SuverStevi2026,
author = {Suver Stević, Mirjana and Periša, Vlatka and Vujičić, Karla and Marczi, Saška and Sinčić-Petričević, Jasminka and Mjeda, Danijela},
title = {One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {14},
pages = {2216},
doi = {10.3390/diagnostics16142216}
}
EUVIMED